A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT02783482 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569 ·Status: COMPLETED ·Phase: PHASE4

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

NCT04565015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

NCT01175213 ·Status: COMPLETED ·Phase: PHASE3

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847 ·Status: COMPLETED ·Phase: PHASE4

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

NCT03492710 ·Status: WITHDRAWN ·Phase: PHASE3

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115 ·Status: COMPLETED ·Phase: PHASE3

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444 ·Status: COMPLETED ·Phase: PHASE3

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

NCT00811174 ·Status: TERMINATED ·Phase: PHASE3

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

NCT03707717 ·Status: COMPLETED ·Phase: PHASE1

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

NCT00001145 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

NCT05603195 ·Status: COMPLETED ·Phase: PHASE1

Study of Belimumab Administered Subcutaneously to Healthy Subjects

NCT01583530 ·Status: COMPLETED ·Phase: PHASE1

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Tolerance and Patients' Satisfaction With IGHy

NCT03668288 ·Status: UNKNOWN

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

NCT01084252 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml

NCT01985373 ·Status: COMPLETED ·Phase: PHASE3

A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma

NCT00675649 ·Status: WITHDRAWN ·Phase: PHASE2

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

NCT03716700 ·Status: COMPLETED

Non-Interventional Study on the Tolerability and Efficacy of IVIG

NCT02303093 ·Status: COMPLETED

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

NCT05292131 ·Status: COMPLETED ·Phase: PHASE1

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341 ·Status: COMPLETED ·Phase: PHASE3

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

NCT03339778 ·Status: COMPLETED

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

NCT02016963 ·Status: COMPLETED ·Phase: PHASE2/PHASE3